You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Multi-Band Airborne SAR/GMTI System Development

    SBC: Applied Radar, Inc.            Topic: AF093138

    A multi-band airborne synthetic aperture radar and ground moving-target indicating (SAR/GMTI) radar system will be designed and developed that will utilize multiple frequency bands to improve the radar imaging and target detection performance in various clutter environments. Applied Radar’s existing wideband digital receiver/exciter (DREX) hardware is inherently capable of supporting radar appli ...

    SBIR Phase I 2010 Department of DefenseAir Force
  2. Promoting Health During Pregnancy: A Multiple Behavior Computer Tailored Interven

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NCCDPHP

    DESCRIPTION (provided by applicant): Pregnant women, particularly those from underserved populations, often have a multitude of behavioral risks that threaten positive pregnancy and birth outcomes, as well as the future health of mother and baby. This application represents innovative research for impacting the promotion of healthy behaviors among pregnant women. The objective is to develop and te ...

    SBIR Phase II 2010 Department of Health and Human ServicesCenters for Disease Control and Prevention
  3. VLP-Based Antibody-Inducing Vaccines for HIV-1

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV-1 infection cannot be prevented by immunization with monomeric recombinant forms of viral envelope (Env) proteins. However, it is clear that the HIV-1 Env contains epitopes that can induce neutralizin ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Improved Vaccines for Influenza B Virus

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Influenza is a major cause of morbidity and mortality around the world. In the United States, seasonal epidemics of flu occur from late fall to early spring affecting all age groups but with especially high rates of infection in children. Serious illness and death are consequences of influenza infection among the elderly, young children, and individuals with o ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Designing Improved HIV-1 Envelope Proteins as Vaccine Candidates

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV-1 infection cannot be prevented by immunization with monomeric recombinant forms of viral envelope (Env) proteins. However, it is clear that the HIV-1 Env contains epitopes that can induce neutralizin ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Immunotherapeutic Biomaterials for Treatment of Glioma

    SBC: IN CYTU, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): A Phase I SBIR program of preclinical development is proposed focusing on the development of an active specific immunotherapeutic called Cellarium for treatment of glial cell-based cancers. Successful completion of this project will establish the minimum level of therapeutic feasibility and lead to further development of the vaccine in preparation for f ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Role of Inter-alpha Inhibitors in Anthrax Intoxication

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Anthrax is recognized as a class A bio-threat microbial pathogen that is readily weaponized and exceedingly difficult to treat. This bacterium is highly virulent inducing lethal infection in immunologically normal hosts by its intrinsic capacity to disseminate rapidly and induce sepsis, along with its ability to generate two highly potent exotoxins, lethal toxi ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Safe, Large-Format Lithium Ion Batteries for Aircraft

    SBC: Yardney Technical Products, Inc.            Topic: AF141071

    YTP will develop technology that provides a high performance, modular Li-ion battery with: redundant safety features, safer thin, metal case cell designs; fin/micro-channel thermal control system; and an evaporating fluid system that rapidly quenches failing cells to prevent thermal runaway and fratricide. The end goal of the proposal is making a lighter, longer lasting, less expensive, safer JSF ...

    SBIR Phase I 2014 Department of DefenseAir Force
  9. SIGMA: Speedy Imagery Geo-registration and Motion Analysis

    SBC: VISION SYSTEMS INC            Topic: AF131151

    ABSTRACT: VSI proposes the development of the SIGMA (Speedy Imagery Geo-registration and Motion Analysis) system, which will address three key requirements by the end of Phase II: (i) adapt to different type of sensors, sensor-configurations and sensor operating conditions, (ii) handle large amount of data in real-time or close to real-time using limited resources, and (iii) operate under conditi ...

    SBIR Phase II 2015 Department of DefenseAir Force
  10. Calcaftor, a CFTR stabilizer for Cystic Fibrosis treatment

    SBC: CALISTA THERAPEUTICS INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold standard pre-clinical model of CF using F508 -CFTR lung tissue harvested from CF transplant patients. Results from this model demonstrated a gt25 hour duration of action that enables once daily inhaled n ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government